Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.46 |
| ▸ | GPR6 | P46095 | 2/20 | 0.38 |
| ▸ | TACR3 | P29371 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 4/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31343043 | 0.92 | CYP3A4 (0.52) | CYP3A4 | |
| SCHEMBL31342995 | 0.89 | CYP3A4 (0.39) | CYP3A4GPR6TACR3KITGPR119 | |
| SCHEMBL31342844 | 0.88 | CYP3A4 (0.44) | CYP3A4 | |
| SCHEMBL31343024 | 0.86 | CYP3A4 (0.41) | CYP3A4GPR6GPR119TNIK | |
| SCHEMBL31342866 | 0.85 | CYP3A4 (0.40) | CYP3A4GPR6KITCHRNB4CHRNA3 | |
| SCHEMBL31342892 | 0.82 | CYP3A4 (0.51) | CYP3A4 | |
| SCHEMBL31342795 | 0.81 | CYP3A4 (0.53) | CYP3A4GPR119 | |
| SCHEMBL31342879 | 0.78 | CYP3A4 (0.43) | CYP3A4GPR119 | |
| SCHEMBL31342913 | 0.78 | CYP3A4 (0.40) | CYP3A4TACR3KITGPR119 | |
| Hydrochloric Acid SCHEMBL31342830 | 0.77 | SLC6A2 (0.40) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049495-A1 | TERTIARY PYRIDYL AMINE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYLINATION | GENENTECH, INC. (US) | 2025-03-06 | — | — | WO | disclosed |